EPM
Steroid Substitutes Based on Synthetic Cannabinoid Acids
Company Overview
Snapshot
Founded in October 2017 by Reshef Swisa, EPM operates with 1–10 employees. The company has raised $2.5M across 4 funding rounds from 4 investors. In March 2021, Key Capital participated in a funding round for EPM.
Business overview
EPM is a Health Tech & Life Sciences company focused on developing prescription medicine derived from synthetic cannabinoid acids. The company's core technology involves the discovery of 14 protected synthetic molecules, including eight novel structures, and associated production process intellectual property. EPM primarily targets metabolic disorders, such as Prader-Willi syndrome, and inflammatory skin diseases like psoriasis, serving the pharmaceutical market with its drug discovery and development efforts.
Strategic signal
In April 2022, the Israeli Securities Authority halted EPM's offering via television, indicating regulatory scrutiny on the company's public offering methods. This event signals potential challenges in EPM's capital raising strategy and highlights the importance of regulatory compliance for companies operating in the pharmaceutical sector, particularly when attempting to reach a broad investor base.
Log in to access full profile ›Company Intelligence Q&A
- What is EPM's primary focus in drug development?
- EPM develops prescription medicine derived from synthetic cannabinoid acids, with a current focus on metabolic disorders like Prader-Willi syndrome and inflammatory skin diseases such as psoriasis.
- When was EPM founded and by whom?
- EPM was founded in October 2017 by Reshef Swisa.
- Which investor participated in a funding round for EPM in March 2021?
- In March 2021, Key Capital participated in a convertible debt funding round for EPM, which was part of the company's overall $2.5M raised across 4 funding rounds.
- What was a significant regulatory event for EPM in April 2022?
- In April 2022, the Israeli Securities Authority halted EPM's offering via television.
- What is EPM's total disclosed funding amount?
- EPM has raised a total of $2.5M across 4 funding rounds, with the latest disclosed funding being convertible debt rounds in November 2020, March 2021, May 2021, and November 2021.